CalciMedica, Inc.
CalciMedica, Inc. (CALC) Stock Overview
Explore CalciMedica, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
28M
P/E Ratio
-1.51
EPS (TTM)
$-1.59
ROE
-1.57%
CALC Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of CalciMedica, Inc. (CALC) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 69.82, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.91.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.51 and a market capitalization of 28M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Analyst Recommendations
Price Targets
Company Profile
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
A. Rachel Leheny
14
505 Coast Boulevard South, La Jolla, CA
2023